<DOC>
	<DOCNO>NCT00324077</DOCNO>
	<brief_summary>The purpose study find whether add new drug , dasatinib , imatinib safe , whether combination two drug help decrease number cell contain Philadelphia chromosome .</brief_summary>
	<brief_title>Phase I Study Dasatinib ( BMS-354825 ) Imatinib Subjects With Chronic Myeloid Leukemia Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>male female , 18 old chronic phase Ph+ BCRABL positive CML current complete hematologic response imatinib lack major molecular response imatinib least one year imatinib dose least 6 month adequate hepatic renal function History accelerate blast phase CML Serious uncontrolled medical disorder active infection Significant cardiovascular disease bleed disorder Concurrent use medication risk cause Torsades de Pointe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Chronic phase chronic myelogenous leukemia ( CML )</keyword>
</DOC>